6 hours Ago By Defense World Staff
Stephens upgraded shares of Azenta ( NASDAQ:AZTA – Free Report ) from an equal weight rating to an overweight rating in a research note released on Wednesday morning, Marketbeat Ratings reports. They currently have $60.00 price target on the stock, up from their previous price target of $50.
00. A number of other brokerages have also issued reports on AZTA. Evercore ISI reduced their price target on Azenta from $53.
00 to $50.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Needham & Company LLC cut their price objective on shares of Azenta from $69.
00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock.
Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $61.60.
View Our Latest Stock Report on Azenta Azenta Stock Up 1.9 % Azenta ( NASDAQ:AZTA – Get Free Report ) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.
18 EPS for the quarter, beating the consensus estimate of $0.10 by $0.08.
The company had revenue of $170.00 million for the quarter, compared to analyst estimates of $169.66 million.
Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%.
Azenta’s revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.
13 earnings per share. Equities analysts forecast that Azenta will post 0.41 EPS for the current fiscal year.
Insider Buying and Selling at Azenta In other Azenta news, Director William L. Cornog purchased 12,500 shares of the company’s stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of $39.
60 per share, for a total transaction of $495,000.00. Following the completion of the transaction, the director now owns 14,755 shares in the company, valued at $584,298.
The trade was a 554.32 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website .
Also, CFO Herman Cueto sold 1,595 shares of the company’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total transaction of $69,669.
60. Following the completion of the sale, the chief financial officer now directly owns 24,604 shares of the company’s stock, valued at $1,074,702.72.
The trade was a 6.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
In the last ninety days, insiders sold 3,018 shares of company stock valued at $126,689. 1.77% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Azenta Hedge funds have recently made changes to their positions in the business. Hantz Financial Services Inc. acquired a new stake in Azenta during the second quarter valued at approximately $30,000.
Farther Finance Advisors LLC lifted its position in shares of Azenta by 20.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after acquiring an additional 256 shares during the last quarter.
Benjamin F. Edwards & Company Inc. lifted its position in shares of Azenta by 150.
9% during the 2nd quarter. Benjamin F. Edwards & Company Inc.
now owns 1,588 shares of the company’s stock valued at $84,000 after acquiring an additional 955 shares during the last quarter. Net Worth Advisory Group bought a new stake in shares of Azenta during the 3rd quarter worth $205,000. Finally, Aigen Investment Management LP acquired a new position in shares of Azenta in the 3rd quarter worth $214,000.
Institutional investors and hedge funds own 99.08% of the company’s stock. Azenta Company Profile ( Get Free Report ) Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. Further Reading Five stocks we like better than Azenta What is a Bond Market Holiday? How to Invest and Trade Opal Fuels CEO on Steering the Future of Renewable Natural Gas Trading Halts Explained MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win What Are Dividend Challengers? 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter .
.
